Cell Therapy News Volume 22.42 | Dec 13 2021

    By
    Justin.choi
    -
    0
    55







    2021-12-13 | CTN 22.42


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.42 – 13 December, 2021
    TOP STORY

    Axicabtagene Ciloleucel as Second-Line Therapy for Large B Cell Lymphoma

    In a Phase III clinical trial, scientists randomly assigned, in a 1:1 ratio, patients with large B cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel or standard care.
    [New England Journal of Medicine]

    Abstract

    This webinar provides insights and techniques for efficient leukopak sample processing and streamlined cell isolation.
    PUBLICATIONSRanked by the impact factor of the journal

    Betibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia

    In this open-label, Phase III study, investigators evaluated the efficacy and safety of beti-cel in adult and pediatric patients with transfusion-dependent β-thalassemia and a non–β0/β0 genotype.
    [New England Journal of Medicine]

    Abstract

    Neurocognitive and Hypokinetic Movement Disorder with Features of Parkinsonism after BCMA-Targeting CAR-T Cell Therapy

    Public transcriptomic datasets confirmed B cell maturation antigen (BCMA) RNA expression in the caudate of normal human brains, suggesting that this may be an on-target effect of anti-BCMA therapy.
    [Nature Medicine]

    Full Article

    Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B Cell Malignancy Patients

    Researchers developed an anti-CD19 CAR comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.
    [Nature Communications]

    Full Article

    Homogeneous Antibody and CAR-T Cells with Improved Effector Functions Targeting SSEA-4 Glycan on Pancreatic Cancer

    The authors showed that SSEA-4 was more expressed in all pancreatic cancer cell lines examined but not detectable in normal pancreatic cells.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Long Noncoding RNA LUCAT1 Enhances the Survival and Therapeutic Effects of Mesenchymal Stromal Cells Post-myocardial Infarction

    Using unbiased transcriptome profiling of hypoxia-preconditioned mesenchymal stem cell and normoxic MSCs, scientists identified a lncRNA named lung cancer-associated transcript 1 (LUCAT1) under hypoxia.
    [Molecular Therapy-Nucleic Acids]

    AbstractFull ArticleGraphical Abstract

    Safe and Efficient In Vivo Hematopoietic Stem Cell Transduction in Nonhuman Primates Using HDAd5/35++ Vectors

    The authors tested a new in vivo hematopoietic stem cell (HSC) transduction/selection approach in rhesus macaques using HSC-tropic, integrating, helper-dependent adenovirus vectors (HDAd5/35++) designed for expression of human γ−globin in red blood cells to treat hemoglobinopathies.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractGraphical Abstract

    CXCR4 Blockade Reduces the Severity of Murine Heart Allograft Rejection by Plasmacytoid Dendritic Cell-Mediated Immune Regulation

    Scientists performed fully-mismatched heart transplantations and found combination treatment to result in prolonged allograft survival.
    [Scientific Reports]

    Full Article

    Stem-Cell Mobilization of Healthy Sibling Donors with Pegfilgrastim—a Prospective Open-Label Phase II Trial (EudraCT No: 2005-004971-39)

    Researchers reported on a Phase II prospective monocentric trial examining the feasibility of stem cell mobilization with 12mg single dose pegfilgrastim in related donors.
    [Transfusion]

    Full Article

    An ISSCR 2021 Innovation Showcase Webinar: Quality by Design in hPSC Cell Therapy, presented by Lynn Csontos & Kimberly Snyder. Click to Watch Now.
    REVIEWS

    Emerging Strategies for Beta Cell Transplantation to Treat Diabetes

    Beta cell replacement has emerged as an attractive therapeutic alternative to traditional exogenous insulin administration for management of type 1 diabetes.
    [Trends in Pharmacological Sciences]

    Abstract

    Neoadjuvant Immune Checkpoint Inhibitors in High-Risk Stage III Melanoma

    Scientists review and discuss the available published and ongoing clinical trials to explore the scientific background behind immunotherapy in the neoadjuvant context.
    [Human Vaccines & Immunotherapeutics]

    Abstract
    INDUSTRY AND POLICY NEWS

    Smart Immune Announces Research Collaboration with Memorial Sloan Kettering Cancer Center (MSK) to Expedite Development of a Next Generation CAR-T Through its Long Lasting, Exhaustion-Free CAR ProTcell™ Platform

    Smart Immune SAS, a clinical stage T-cell medicine company utilizing its proprietary ex vivo biomimetic “thymus-in-a-dish” technology to develop T cell progenitors to reset a rapid, safe and full immune reconstitution, announced today a research collaboration with MSK.
    [Smart Immune SAS]

    Press Release

    Be the Match BioTherapies® and Vineti Collaborate to Develop Innovative, Integrated Supply Chain Management Solutions for Cell and Gene Therapies

    Be The Match BioTherapies® and Vineti, the provider of the leading digital enterprise platform for cell and gene therapy supply chains, announced a collaboration to develop joint solutions that simplify and scale supply chain management of cell and gene therapies.
    [Vineti (GlobeNewsWire, Inc.)]

    Press Release
    FEATURED EVENT

    Gene Regulation: From Emerging Technologies to New Models

    January 23 – 26, 2022
    Santa Fe, New Mexico, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – CAR T Cells Engineered to Treat Multiple Myeloma

    Memorial Sloan Kettering – New York City, New York, United States

    Research Fellow – Stem Cell-Based Therapies

    iCamuno Biotherapeutics – Melbourne, Australia

    Postdoctoral Research Fellow – Immunotherapy, Stem Cell Transplantation and GVHD

    Fred Hutch – Seattle, Washington, United States

    Postdoctoral Researcher – Therapeutic Targets

    Flanders Institute for Biotechnology – Leuven, Belgium

    Scientific Researcher – Cancer Immunology

    Genentech – San Francisco, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter